Sampo plc
16.1.2026 07:30:00 CET | Globenewswire | Press release
Sampo plc’s share buybacks 15 January 2026
Sampo plc’s share buybacks 15 January 2026
Sampo plc, stock exchange release, 16 January 2026 at 8:30 am EET
Sampo plc’s share buybacks 15 January 2026
On 15 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:
| Sampo plc’s share buybacks | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares* | Market (MIC Code) |
| 14,331 | 10.00 | AQEU | |
| 108,090 | 10.01 | CEUX | |
| 36,455 | 10.01 | TQEX | |
| 118,583 | 10.01 | XHEL | |
| TOTAL | 277,459 | 10.01 |
* rounded to two decimals
On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025, is based on the authorisation granted by Sampo's Annual General Meeting on 23 April 2025.
After the disclosed transactions, the company owns in total 11,914,029 Sampo A shares representing 0.45 per cent of the total number of shares in Sampo plc.
Details of each transaction are included as an appendix of this announcement.
On behalf of Sampo plc,
Morgan Stanley
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Kyowa Kirin3.3.2026 14:00:00 CET | Press release
Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials
T-knife Therapeutics3.3.2026 14:00:00 CET | Press release
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
ZenaTech Inc.3.3.2026 13:30:00 CET | Press release
ZenaTech’s ZenaDrone Advances U.S. Defense and Congressional Engagement with Blue UAS-Aligned Drone Development
Synchronoss Technologies, Inc.3.3.2026 13:30:00 CET | Press release
Jelly Toast Launches in India to Simplify Everyday Celebrations
Brookfield Asset Management Ltd3.3.2026 13:00:00 CET | Press release
BCI, Norges Bank Investment Management and Brookfield Partner to Launch Northview Energy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom